Listed

Astrana Health, Inc.: Form 10-Q for the period ended Mar 31, 2023

Filed with the SEC on May 10, 2023 and accepted by EDGAR at May 10, 2023, 13:49 ET.

Share

Management's discussion and analysis

As filed, 31,325 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited consolidated financial statements and the notes thereto included in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 1, 2023.

Overview

Apollo Medical Holdings, Inc. is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, ApolloMed operates an integrated, value-based healthcare model, which aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner. Together with our affiliated physician groups and consolidated entities, we provide coordinated outcomes-based medical care in a cost-effective manner.

The majority of our patients are covered by private or public insurance provided through Medicare, Medicaid, and health maintenance organizations (“HMOs”). However, a small portion of our revenue comes from non-insured patients. We provide care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Our physician network consists of primary care physicians, specialist physicians, physician and specialist extenders, and hospitalists. We operate primarily through Apollo Medical Holdings, Inc. (“ApolloMed”) and the following subsidiaries: NMM, AMM, and APAACO and their consolidated entities, including consolidated VIEs. Refer to Note 2 — “Basis of Presentation and Summary of Significant Accounting Policies” to our consolidated financial statements under Item 1 in this Quarterly Report on Form 10-Q for all consolidated entities.

Led by a management team with several decades of experience, we focus on physicians providing high-quality medical care, population health management, and patient care coordination. As a result, we are well-positioned to take advantage of the shift in the U.S. healthcare industry toward providing value-based and results-oriented healthcare with a focus on patient satisfaction, high-quality care, and cost efficiency.

Through our accountable care organization and a network of IPAs with more than 12,000 contracted physicians, we are responsible for coordinating care in value-based care arrangements for approximately 1.3 million patients primarily in California as of March 31, 2023.

Recent and Other Developments

On May 1, 2023, the Company closed its purchase of For Your Benefit Inc. (“FYB”). FYB is affiliated with AAMG and is licensed by the California Department of Managed Health Care as a full-service Restricted Knox-Keene licensed health plan, which enables FYB to assume full financial responsibility, including both professional and institutional risk, for the medical costs of its members under the Knox-Keene Health Care Service Plan Act of 1975.

Key Financial Measures and Indicators

Operating Revenues

Our revenue, which is recorded in the period in which services are rendered and earned, primarily consists of capitation revenue, risk pool settlements and incentives, GPDC/ACO REACH revenue, management fee income, and fee-for-services (“FFS”) revenue. The form of billing and related risk of collection for such services may vary by type of revenue and the customer.

Operating Expenses

Our largest expenses consist of the cost of: (i) patient care paid to contracted providers; (ii) information technology equipment and software, and; (iii) hiring staff to provide management and administrative support services to our affiliated physician groups, as further described in the following sections. These services include claims processing, utilization management, contracting, accounting, credentialing, and administrative oversight.

Results of Operations

Consolidated Statements of Income

(In thousands)

(Unaudited)

Revenue Three Months Ended March 31, 2023 2022 $ Change % Change
Capitation, net $300,204 $222,060 $78,144 35%
Risk pool settlements and incentives 13,462 18,075 (4,613) (26)%
Management fee income 9,896 10,473 (577) (6)%
Fee-for-services, net 12,062 11,095 967 9%
Other income 1,620 1,555 65 4%
Total revenue 337,244 263,258 73,986 28%
Operating expenses
Cost of services, excluding depreciation and amortization 289,397 220,730 68,667 31%
General and administrative expenses 21,182 11,943 9,239 77%
Depreciation and amortization 4,292 4,374 (82) (2)%
Total expenses 314,871 237,047 77,824 33%
Income from operations 22,373 26,211 (3,838) (15)%
Other expense
Income from equity method investments 2,484 1,433 1,051 73%
Interest expense (3,269) (1,073) (2,196) 205%
Interest income 3,009 46 2,963 *
Unrealized loss on investments (6,392) (8,962) 2,570 (29)%
Other income 1,204 613 591 96%
Total other expense, net (2,964) (7,943) 4,979 (63)%
Income before provision for income taxes 19,409 18,268 1,141 6%
Provision for income taxes 5,102 6,195 (1,093) (18)%
Net income 14,307 12,073 2,234 19%
Net loss attributable to non-controlling interest (315) (2,191) 1,876 (86)%
Net income attributable to Apollo Medical Holdings, Inc. $14,622 $14,264 $358 3%

* Percentage change of over 500%

54

Net Income Attributable to Apollo Medical Holdings, Inc.

Our net income attributable to Apollo Medical Holdings, Inc. for the three months ended March 31, 2023 was $14.6 million, as compared to $14.3 million for the same period in 2022, an increase of $0.4 million.

Physician Groups and Patients

As of March 31, 2023 and 2022, we managed a total of 15 and 12 independent physician groups that are affiliated and non-affiliated, respectively. The total number of patients for whom we managed the delivery of healthcare services was approximately 1.3 million and 1.2 million, respectively.

Revenue

Our revenue for the three months ended March 31, 2023 was $337.2 million, as compared to $263.3 million for the three months ended March 31, 2022, an increase of $74.0 million, or 28%. The increase in revenue was primarily attributable to the capitation revenue. Capitation revenue increased by approximately $78.1 million driven by organic membership growth in our core IPAs and increased participation in a value-based Medicare fee-for-service model.

Cost of Services, Excluding Depreciation and Amortization

Expenses related to cost of services for the three months ended March 31, 2023 were $289.4 million, as compared to $220.7 million for the same period in 2022, an increase of $68.7 million. The overall increase was primarily due to increased participation in a value-based Medicare fee-for-service model and growth in membership, which was commensurate to our increase in revenue.

General and Administrative Expenses

General and administrative expenses for the three months ended March 31, 2023 were $21.2 million, as compared to $11.9 million for the same period in 2022, an increase of $9.2 million, or 77%. The increase is primarily due to an increase in headcount and other general and administrative expenses to support operational growth.

Depreciation and Amortization

Depreciation and amortization expenses for the three months ended March 31, 2023 were $4.3 million, as compared to $4.4 million for the same period in 2022. This amount includes depreciation of property and equipment and the amortization of intangible assets.

Income (Loss) From Equity Method Investments

Income from equity method investments for the three months ended March 31, 2023 was $2.5 million, as compared to $1.4 million for the same period in 2022, an increase of $1.1 million. The increase in income from equity method investments was primarily due to APC’s equity method investment in LMA. For the three months ended March 31, 2023 and 2022, APC recognized income from this investment of $2.2 million and $1.3 million, an increase of $0.9 million.

Interest Expense

Interest expense for the three months ended March 31, 2023 was $3.3 million, as compared to $1.1 million for the same period in 2022, an increase of $2.2 million. The increase in interest expense was due to higher interest rates. On March 31, 2023, the interest rate on the Amended Credit Agreement was 6.36% compared to 2.38% on March 31, 2022.

Interest Income

Interest income for the three months ended March 31, 2023 was $3.0 million compared to $46,000 for the three months ended March 31, 2022. The increase in interest income is due to more bank accounts becoming interest-bearing. Interest income reflects interest earned on cash held in bank accounts, money market and certificate of deposit accounts and the interest from notes receivable.

Unrealized Loss on Investments

Unrealized loss for the three months ended March 31, 2023 was $6.4 million, as compared to $9.0 million for the same period in 2022, a decrease in unrealized loss of $2.6 million. The decrease in unrealized loss on investments was primarily driven by fluctuations in the stock price from one of the investments we hold shares in. The change in the stock price was smaller for the three months ended March 31, 2023 compared to the three months ended March 31, 2022, resulting in the decrease.

Other Income

Other income for the three months ended March 31, 2023 was $1.2 million, as compared to other income of $0.6 million for the same period in 2022, an increase of $0.6 million. The increase in other income was primarily due to an increase in rental income from APC’s consolidated entities.

Provision for Income Taxes

Provision for income taxes was $5.1 million for the three months ended March 31, 2023 as compared to provision for income taxes of $6.2 million for the same period in 2022, a decrease of $1.1 million. The decrease in provision for income taxes was due to a lower effective tax rate.

Net Loss Attributable to Non-controlling Interests

Net loss attributable to non-controlling interests for the three months ended March 31, 2023 was $0.3 million, as compared to net loss attributable to non-controlling interests for the three months ended March 31, 2022 of $2.2 million, respectively, an increase in net income attributable to non-controlling interest of $1.9 million. The increase was primarily driven by a decrease in unrealized loss resulting from the change in the fair value of our marketable securities related to shares held of a payor partner.

2023 Guidance

ApolloMed is reiterating the following guidance for total revenue, net income, EBITDA, Adjusted EBITDA, and EPS - diluted, based on the Company’s existing business, current view of existing market conditions and assumptions for the year ending December 31, 2023.

($ in millions)

2023 Guidance Range Low High
Total revenue $1,300.0 $1,500.0
Net income $49.5 $71.5
EBITDA $89.5 $129.5
Adjusted EBITDA $120.0 $160.0
EPS – diluted $0.95 $1.20

See “Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA” and “Use of Non-GAAP Financial Measures” below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward-Looking Statements” below for additional information.

Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA

(in thousands)

2023 Guidance Range Low High
Net income $49,500 $71,500
Interest expense 1,000 1,000
Provision for income taxes 23,000 38,000
Depreciation and amortization 16,000 19,000
EBITDA 89,500 129,500
Loss (income) from equity method investments (750) (750)
Other, net 3,250 3,250
Stock-based compensation 16,000 16,000
APC excluded assets costs 12,000 12,000
Adjusted EBITDA $120,000 $160,000

Set forth below are reconciliations of Net Income to EBITDA and Adjusted EBITDA for the three months ended March 31, 2023 and 2022:

(in thousands)

Reconciliation of Net Income to EBITDA and Adjusted EBITDA Three Months Ended March 31, 2023 2022
Net income $14,307 $12,073
Interest expense 3,269 1,073
Interest income (3,009) (46)
Provision for income taxes 5,102 6,195
Depreciation and amortization 4,292 4,374
EBITDA 23,961 23,669
Income from equity method investments (249) (148)
Other, net 1,402 (1) —
Stock-based compensation 3,445 3,055
APC excluded assets costs 1,266 7,784
Adjusted EBITDA $29,825 $34,360 (2)

(1) Other, net for the three months ended March 31, 2023 relates to changes in the fair value of our financing obligation to purchase the remaining equity interest in one of our investments.

(2) Adjusted EBITDA under the historical method for the three months ended March 31, 2022 was $38.2 million. See “Use of Non-GAAP Financial Measures” below for additional information on change of methodology.

Use of Non-GAAP Financial Measures

This Quarterly Report on Form 10-Q contains the non-GAAP financial measures EBITDA and Adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles (“GAAP”) is net income. These measures are not in accordance with, or alternatives to GAAP, and may be different from other non-GAAP financial measures used by other companies. The Company uses Adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, and APC excluded assets costs. Beginning in the third quarter ended September 30, 2022, the Company has revised the calculation for Adjusted EBITDA to exclude provider bonus payments and losses from recently acquired IPAs, which it believes to be more reflective of its business.

The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company’s ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.

Liquidity and Capital Resources

Cash, cash equivalents, and investment in marketable securities at March 31, 2023 totaled $278.7 million as compared to $293.6 million at December 31, 2022. Working capital totaled $292.7 million at March 31, 2023, as compared to $287.8 million at December 31, 2022, an increase of $4.9 million.

We have historically financed our operations primarily through internally generated funds. We generate cash primarily from capitation contracts, risk pool settlements and incentives, fees for medical management services provided to our affiliated physician groups, and FFS reimbursements. We generally invest cash in money market accounts, which are classified as cash and cash equivalents. We believe we have sufficient liquidity to fund our operations through at least the next 12 months.

Our cash and cash equivalents decreased by $13.4 million from $288.0 million at December 31, 2022, to $274.6 million at March 31, 2023. Cash provided by operating activities for the three months ended March 31, 2023 was $7.7 million, as compared to cash provided by operating activities of $24.0 million for the three months ended March 31, 2022. The decrease in cash provided by operating activities was primarily driven by changes in net income and working capital. For the three months ended March 31, 2023, net income exclusive of depreciation and amortization, amortization of debt issuance cost, share-based compensation, unrealized gains or losses, income or loss from equity method investments, and deferred tax was $27.0 million compared to $29.3 million for the three months ended March 31, 2022. Working capital for the three months ended March 31, 2023 decreased operating cash flow by $19.3 million, compared to a $5.2 million decrease in operating cash flow at March 31, 2022. The change in working capital for the three months ended March 31, 2023 was mainly driven by an increase in receivables, net, and increase in medical liabilities related to the Company’s participation in value-based Medicare fee-for-service model, increase in related party receivables primarily related to risk pool settlements, decrease in accounts payable and accrued liabilities, and decrease in income tax receivable

Cash used in investing activities during the three months ended March 31, 2023 was $14.0 million, primarily due to deposit for purchase of property of $8.8 million, purchases of property and equipment of $6.0 million, purchase of marketable securities of $1.0 million, and purchase of an equity method investment of $0.3 million. The cash used in investing activities was partially offset by proceeds from repayment of a loan receivable of $2.1 million. Cash used in investing activities during the three months ended March 31, 2022 was $19.7 million, primarily due to purchases of property and equipment of $17.5 million, payments for business acquisition of $1.0 million, and funding for an equity method investment of $1.4 million. The cash used in investing activities was partially offset by a distribution received from an equity method investment of $0.2 million.

Cash used in financing activities during the three months ended March 31, 2023 was $7.1 million as compared to cash provided by financing activities of $0.5 million for the three months ended March 31, 2022. Cash used in financing activities during the three months ended March 31, 2023 was primarily due to repurchase of treasury stock of $9.5 million, dividend payments of $0.1 million, repayment of debt of $0.2 million, and a repayment of finance lease obligations of $0.2 million. This was partially offset by borrowings from bank loans totaling $1.6 million and proceeds from the exercise of options of $1.3 million. Cash provided by financing activities for the three months ended March 31, 2022 was primarily due to a borrowing on Tag 8’s Construction Loan for $0.7 million and proceeds from the exercise of options and warrants of $1.6 million. This was partially offset by dividend payment of $1.2 million, repurchase of shares of $0.2 million, purchase of non-controlling interest of $0.2 million and repayment of finance lease obligations of $0.1 million.

Excluded Assets

In September 2019, APC and AP-AMH entered into Second Amendment to Series A Preferred Stock Purchase Agreement, which clarified the term excluded assets (“Excluded Assets”). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred Stock equal to the Series A Purchase Price (as defined in the purchase agreement), (ii) the assets of APC that are not Healthcare Services Assets (as defined in the purchase agreement), including APC’s equity interests in Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii).

The Excluded Assets as of March 31, 2023 are primarily comprised of assets and liabilities from operating real estate and proceeds from the sale of UCI. Any dividends issued to APC shareholders are paid using cash from Excluded Assets. As of March 31, 2023 and December 31, 2022, the Excluded Assets balance consisted of the following (in thousands):

March 31, 2023 December 31, 2022
Cash and cash equivalents $16,141 $30,163
Investment in marketable securities 1,538 4,543
Land, property, and equipment, net 106,299 101,349
Investments in other entities – equity method 29,758 27,561
Other receivables and assets 12,495 3,907
Other liabilities (3,314) (4,754)
Long-term debt (28,586) (27,264)
Total Excluded Assets $134,331 $135,505
March 31, 2023 March 31, 2022
Total operating expenses $919 $541
Total other (expense) income, net $(878) $(7,534)
Excluded Assets net loss $(1,798) $(8,075)

59

Credit Facilities

The Company’s debt balance consisted of the following (in thousands):

March 31, 2023
Revolver Loan $180,000
Real Estate Loans 23,015
Construction Loans 5,632
Total debt 208,647
Less: Current portion of debt (621)
Less: Unamortized financing costs (3,082)
Long-term debt $204,944

The following are the future commitments of the Company’s debt for the years ending December 31 (in thousands) below:

Amount
2023 (excluding the three months ended March 31, 2023) $466
2024 6,274
2025 7,184
2026 180,454
2027 472
Thereafter 13,797
Total $208,647

Credit Agreement

On June 16, 2021, the Company entered into an amended and restated credit agreement (the “Amended Credit Agreement” and the credit facility thereunder, the “Amended Credit Facility”) with Truist Bank, in its capacities as administrative agent for the lenders (in such capacity, the “Agent”), issuing bank, swingline lender and a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders (the “Lenders”), and Bank of the West, The Toronto-Dominion Bank, New York Branch, Well Fargo, National Association, and City National Bank in their capacities as Lenders, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, certain Lenders and the Agent (the credit facility thereunder, the “Credit Facility”), in its entirety.

The Amended Credit Agreement provides for a five-year revolving credit facility (“Revolver Loan”) to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement remain in effect.

The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis.

On December 20, 2022, an amendment was made to the Amended Credit Facility, in which all amounts borrowed under the Amended Credit Agreement as of the effective date shall be automatically converted from LIBOR Loans to SOFR Loans with an initial interest period of one month on and as of the amendment effective date.

Refer to Note 9 — “Credit Facility, Bank Loans, and Lines of Credit” to our consolidated financial statements under Item 1 in this Quarterly Report on Form 10-Q for additional information.

Deferred Financing Costs

In September 2019, the Company recorded deferred financing costs of $6.5 million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7 million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility.

Effective Interest Rate

The Company’s average effective interest rate on its total debt during the three months ended March 31, 2023 and 2022 was 5.69% and 1.78%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three months ended March 31, 2023 and 2022 of $0.2 million and $0.2 million, respectively.

Real Estate Loans

On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in MPP, AMG Properties, and ZLL. As a result of the purchase on the date of acquisition, APC assumed $6.4 million, $0.7 million, and $0.7 million of existing loans held by MPP, AMG Properties, and ZLL, respectively. Refer to Note 9 — “Credit Facility, Bank Loans, and Lines of Credit” to our consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information.

On January 25, 2022, 120 Hellman entered into a real estate loan agreement with MUFG Union Bank N.A. and borrowed $16.3 million. Refer to Note 9 — “Credit Facility, Bank Loans, and Lines of Credit” to our consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information.

Construction Loans

In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (“Construction Loan”) that allows Tag 8 to borrow up to $10.7 million. Tag 8 is a VIE consolidated by the Company. Refer to Note 9 — “Credit Facility, Bank Loans, and Lines of Credit” to our consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information.

Intercompany Loans

Each of AMH, MMG, AKM Medical Group, Inc. (“AKM”), SCHC, and Bay Area Hospitalist Associates (“BAHA”) has entered into an Intercompany Loan Agreement with AMM under which AMM has agreed to provide a revolving loan commitment to each such affiliated entity in an amount set forth in each Intercompany Loan Agreement. Each Intercompany Loan Agreement with AMM provides that AMM’s obligation to make any advances automatically terminates upon the termination of the management agreement with the applicable affiliated entity. In addition, each Intercompany Loan Agreement provides that (i) any material breach by the shareholder of record of the applicable Physician Shareholder Agreement, or (ii) the termination of the management agreement with the applicable affiliated entity constitutes an event of default under the Intercompany Loan Agreement. All the intercompany loans have been eliminated in consolidation (in thousands).

Jade entered into an Intercompany Loan Agreement with NMM, pursuant to which NMM agreed to provide a revolving loan commitment to Jade. The Intercompany Loan agreement between NMM and Jade matures on June 1, 2024.

Entity Intercompany Credit Facility Interest Rate per Annum Three months ended March 31, 2023 Maximum Balance During Period Ending Balance Principal Paid During Period Interest Paid During Period
AMH $10,000 10% $6,588 $6,588 $— $—
MMG 3,000 10% 3,663 3,663 — —
AKM 5,000 10% — — — —
SCHC 5,000 10% 5,362 5,362 — —
BAHA 250 10% 4,066 3,945 — —
Jade 10,000 5% 5,000 5,000 — —
$33,250 $24,679 $24,558 $— $—

Critical Accounting Policies and Estimates

The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires our management to make judgments, assumptions, and estimates that affect the amounts of revenue, expenses, income, assets, and liabilities, reported in our consolidated financial statements and accompanying notes. Actual results and the timing of recognition of such amounts could differ from those judgments, assumptions, and estimates. In addition, judgments, assumptions, and estimates routinely require adjustment based on changing circumstances and the receipt of new or better information. Understanding our accounting policies and the extent to which our management uses judgment, assumptions, and estimates in applying these policies, therefore, is integral to understanding our financial statements. Critical accounting policies and estimates are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions. We summarize our most significant accounting policies in relation to the accompanying consolidated financial statements in Note 2 — “Basis of Presentation” thereto. Please also refer to the Critical Accounting Policies section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

Off-Balance Sheet Arrangements

As of March 31, 2023, we had no off-balance sheet arrangements that are or have been reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.

Inflation

Inflation and changing prices have had a de minimis effect on our continuing operations over our two most recent fiscal years.

Market risk

As filed, 2,776 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Interest Rate Risk

Borrowings under our Amended Credit Agreement exposed us to interest rate risk. As of March 31, 2023, we had $180.0 million in outstanding borrowings under our Amended Credit Agreement. The amount borrowed under the Amended Credit Agreement bears interest at an annual rate equal to either, at the Company’s option, (a) the Term SOFR Reference Rate, calculated two U.S. Government Securities Business Days prior to the first day of such interest period, as such rate is published by the Term SOFR Administrator (Federal Reserve Bank of New York), adjusted for any Term SOFR Adjustment, plus a spread of from 1.25% to 2.50%, as determined on a quarterly basis based on the Company’s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.50%, as determined on a quarterly basis based on the Company’s leverage ratio. In addition, as of March 31, 2023, Tag 8, a VIE consolidated by the Company, had $5.6 million in outstanding borrowings for the Construction Loan. Interest rate on the Construction Loan is equal to an index rate determined by the bank. Furthermore, as of March 31, 2023, APC had $23.0 million in outstanding borrowings for real estate loans related to ZLL, MPP, AMG Properties, and 120 Hellman (“Real Estate Loans”).The Real Estate Loans with ZLL, MPP, and AMG Properties bear interest that is subject to change from time to time based on changes in an independent index, which is the daily *Wall Street Journal “*Prime Rate”, as quoted in the “Money Rates” column of The Wall Street Journal (Western edition) as determined by the Lender (the “Index”). On the dates of the agreement, the Index is 3.25% per annum. Under no circumstances will the interest rate on this loan be less than 3.50% per annum or more than the maximum rate allowed by applicable law. 120 Hellman’s Real Estate Loan has a variable interest rate of 2.0% in excess of Daily Simple SOFR, which is the daily rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. The Company has entered into interest rate swap agreements and collar agreements for certain agreements to effectively convert its floating-rate debt to a fixed-rate basis or to a rate within the agreed upon range. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company’s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. A hypothetical 1% change in our interest rates for our outstanding borrowings under our Credit Agreement, Construction Loans, and Real Estate Loans would have increased or decreased our interest expense for the year ended March 31, 2023 by $2.1 million.

Controls and procedures

As filed, 1,416 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

As of March 31, 2023, we carried out an evaluation, under the supervision and with the participation of our management, including our Co-Chief Executive Officers and Interim Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, our management, including Co-Chief Executive Officers and Interim Chief Financial Officer, concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15(d)-15(e) under the Exchange Act, were effective as of March 31, 2023 to ensure that information required to be disclosed by us in this Quarterly Report on Form 10-Q or submitted under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and (ii) accumulated and communicated to our management, including our principal executive officers and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under Exchange Act) during our first fiscal quarter of 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 2,617 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our business, financial condition, and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry, as well as risks that affect businesses in general. In addition to the information and risk factors set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 1, 2023. The risks disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows, or results of operations and thus our stock price. We believe there have been no material changes in our risk factors from those disclosed in the Annual Report. However, additional risks and uncertainties not currently known or which we currently deem to be immaterial may also materially adversely affect our business, financial condition, or results of operations.

These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the consolidated financial statements and related notes in Part I, Item 1, “Financial Statements” and Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Quarterly Report on Form 10-Q. Because of such risk factors, as well as other factors affecting the Company’s financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.

We currently, and may in the future, have assets held at financial institutions that exceed the insurance coverage offered by the Federal Deposit Insurance Corporation, the loss of such assets would have a severe negative affect on our operations and liquidity.

We maintain our cash assets at certain financial institutions in the U.S. in amounts that are significantly in excess of the FDIC insurance limit of $250,000. As of March 31, 2023, our deposit accounts with banks exceeded the FDIC’s insured limit by approximately $306.5 million. In the event of a failure of any financial institutions where we maintain our deposits or other assets, we may incur a significant loss to the extent such loss exceeds the FDIC insurance limitation, which could have a material adverse effect upon our liquidity, financial condition and our results of operations.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-01-01 to 2023-03-31$337.2mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Operating income3 months2023-01-01 to 2023-03-31$22.4mus-gaap:OperatingIncomeLoss
Interest expense3 months2023-01-01 to 2023-03-31$3.3mus-gaap:InterestExpense
Income tax3 months2023-01-01 to 2023-03-31$5.1mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-01-01 to 2023-03-31$14.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-01-01 to 2023-03-31$0.31us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-01-01 to 2023-03-31$0.31us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-01-01 to 2023-03-3146,954,687 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2023-01-01 to 2023-03-31$7.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2023-01-01 to 2023-03-31$6.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases3 months2023-01-01 to 2023-03-31$0us-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2023-03-31$274.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-03-31$457.7mus-gaap:AssetsCurrent
Total assetsAt period end2023-03-31$992.6mus-gaap:Assets
Current liabilitiesAt period end2023-03-31$165.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-03-31$414.7mus-gaap:Liabilities
Long-term debtAt period end2023-03-31$204.9mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2023-03-31$621.0kus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2023-03-31$560.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001628280-23-017118. Last ingested by Listed: Nov 14, 2026, 19:58 ET. Listed shows no prices and gives no investment advice.